DDInter1266 DDInter1566
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Naproxen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Naproxen {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Naproxen {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Naproxen {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Naproxen {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Naproxen {u} (Compound) causes {v} (Side Effect) Infection
Infection {u} (Side Effect) is caused by {v} (Compound) Milnacipran
Milnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Naproxen {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may lead to a major life threatening interaction when taken with Ramucirumab
Naproxen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab and Flurbiprofen may lead to a major life threatening interaction when taken with Ramucirumab
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Naproxen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Naproxen (Compound) resembles Ketoprofen (Compound) and Ketoprofen (Compound) resembles Nepafenac (Compound) and Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Naproxen (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Naproxen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Ramucirumab
Naproxen (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Milnacipran (Compound) and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Naproxen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Acetylsalicylic acid (Compound) and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Ramucirumab